The FDA has classified Boston Scientific’s removal of certain Axios Stent and Electrocautery-Enhanced Delivery Systems as a Class I recall, the agency’s most serious designation. The recall stems from ...
BSX's Endoscopy revenues rose 6% to $673M in Q1 2025, making up 14% of total company sales. Growth was fueled by strong global demand and high adoption of BSX's advanced GI treatment technologies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results